Sarepta Therapeutics | SRPT - Operating Expenses

Stock Price
17.55
Daily Change
-1.13 -6.05%
Monthly
-17.10%
Yearly
-51.83%
Q2 Forecast
17.20

Sarepta Therapeutics reported $372.37M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
BioCryst Pharmaceuticals USD -553.84M 700.01M Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Capricor Therapeutics USD 29.16M 2.87M Dec/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Gilead Sciences USD 23.52B 18.55B Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
Insmed USD 506.24M 7.31M Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Moderna USD 1.78B 242M Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Novavax USD 126.2M 23.62M Dec/2025
Pfizer USD 90.1B 77.19B Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sanofi EUR 9.31B 1.2B Mar/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Tectonic Therapeutic USD 21.52M 374K Dec/2025
Ultragenyx Pharmaceutical USD 305M 16M Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026